To amend title XXVII of the Public Health Service Act and title XIX of the Social Security Act to require coverage of Alzheimer's biomarker testing under group health plans, group and individual health insurance coverage, and the Medicaid program.
About This Bill
Committee
Latest Action · July 22, 2026
Referred to the House Committee on Energy and Commerce.
The Alzheimer's Early Detection Act of 2026 requires private health insurance plans and Medicaid to cover Alzheimer's biomarker testing, which includes blood tests and other diagnostic procedures used to detect, diagnose, and monitor Alzheimer's disease. The bill applies to all group health plans, individual health insurance policies, and state Medicaid programs, ensuring that people with insurance have access to these early detection tests. Insurance companies cannot impose stricter cost-sharing or prior authorization requirements for these tests than they do for other medical procedures, and they must approve or deny authorization requests within 24 to 72 hours. The coverage requirements take effect one year after the bill becomes law for private insurance and one year after enactment for Medicaid. Additionally, the National Institutes of Health must conduct a study through the National Academies of Sciences, Engineering, and Medicine to assess the effectiveness of biomarker testing in detecting and treating Alzheimer's disease, with reports due annually for three years.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.